Kamis, 21 Oktober 2010

Grapevine Clinic Charged With Offering Unauthorized Birth Control Products

Texas Attorney General Greg Abbott Texas Attorney General Greg Abbott
FOR IMMEDIATE RELEASE
October 21, 2010
www.texasattorneygeneral.gov
Subscribe to E-News
CONTACT
Press Office at
(512) 463-2050

Grapevine Clinic Charged With Offering Unauthorized Birth Control Products

Women’s Integrated Healthcare cited for purchasing and selling unapproved IUDs to patients

FORT WORTH – Texas Attorney General Greg Abbott today took legal action against a Grapevine women’s health clinic for purchasing and selling intrauterine devices (IUDs) that were not approved for sale in the United States.

The State’s legal action stems from a referral by the Texas Department of State Health Services (DSHS). It names Women’s Integrated Healthcare, P.A. and six of its physicians as defendants: Angela L. Cope, M.D.; Barbara Coulter-Smith, D.O.; Katrina E. Allen, M.D.; Courtney Walters, M.D.; Monica E. Lopez, M.D.; and Wendy A. Kendrick, D.O.

According to court documents filed by the State, Women’s Integrated Healthcare first obtained unapproved IUDs in April 2008. The IUDs were ordered from an online Canadian pharmacy called Medisave. Although the manufacturer, Bayer, produces Mirena® IUDs that are approved for use in the U.S. by the Food and Drug Administration (FDA), the defendants sought to reduce acquisition costs and thus purchased unapproved IUDs.

All Mirena® IUDs are manufactured in Finland by Bayer Schering Pharma OY. However, only one version of the Mirena® IUD has been approved by the FDA for use in the U.S. To obtain federal approval, Bayer filed a required “new drug application” in late 2000. The approved version of the IUD contains a birth control drug called “levonorgestrel,” which prompted the manufacturer’s new drug application with the FDA. After FDA approval was granted, licensed drug distributor TheraCom began distributing the Mirena® IUD in the U.S.

According to DSHS, Bayer indicated to state authorities that the IUD approved in the U.S. differs from those sold in other countries. Among the disparities between the approved and unapproved IUDs are design differences, lower cost, alternate package labeling and non-English medical warnings. Additionally, because the IUDs were procured from a Canadian pharmacy rather than a licensed drug distributor, the products were not stored or transported through licensed distribution channels.

The State’s enforcement action indicates that Bayer issued a warning to U.S. health care professionals in 2008. The manufacturer’s warning informed physicians who had previously purchased the FDA-approved Mirena® IUD – including the defendants – that purchasing, distributing, possessing and selling the unapproved IUDs to U.S. patients was unlawful.

Court documents filed by the State also indicate that the unapproved IUDs’ packaging contained health advisory information and physician instructions that were printed in Scandinavian languages – not in English. Under federal law, all information on the labels and inserts must be printed in English. The defendants attempted to resolve the situation by removing the foreign labeling and inserting an English language warning downloaded from Bayer’s website. However, because the packaging itself was not in English, the prescription products are misbranded and therefore could not be lawfully distributed in the U.S.

In December 2009, the defendants voluntarily stopped selling and administering the unapproved IUDs. To ensure future compliance with the law, the Office of the Attorney General is seeking a court order requiring that the defendants only purchase and sell FDA-approved IUDs. The State is also seeking to ensure that such products purchased by the defendants are properly labeled in English. Additionally, the State is seeking civil penalties for violations of the Texas Deceptive Trade Practices Act and the Texas Health and Safety Code.

Tidak ada komentar:

Posting Komentar